Nonetheless, the overall results indicated that the serological gastric function strategy, characterized by stringent prescription controls, proved to be effective in enhancing the appropriateness of patient selection for upper gastrointestinal endoscopy not only in regions with high GC incidence but also in medium-risk regions, as also further confirmed in a recent study [163], while the management of H. pylori was found to be useful in reducing GC development [164] and gastrin G17 in the diagnosis of autoimmune atrophic gastritis [165,166]. Here, GAST is linked to gastric cancer.